>MNTA – I think my view of FDA is jaded. Whatever is the worst case is what I have come to expect from them. Anything better will be a bonus.<
I’d like to draw a distinction between what an investment decision is predicated on and what one thinks will actually occur. On the latter we’re pretty far apart, but on the former I think we’re in full agreement: MNTA is a buy even if we assume that the FDA will demand human trials to allay the immunogenicity concern.
Market Data 
Markets 
AI
